Skip to main content
Fig. 6 | BMC Medicine

Fig. 6

From: m6A regulator expression profile predicts the prognosis, benefit of adjuvant chemotherapy, and response to anti-PD-1 immunotherapy in patients with small-cell lung cancer

Fig. 6

The predictive value of the m6A score for the benefit of adjuvant chemotherapy in different cohorts. A Kaplan-Meier curves of OS in patients with adjuvant chemotherapy in the international cohort. B ROC analysis of m6A score for the prediction of OS at 1, 3, and 5 years in patients with adjuvant chemotherapy in the international cohort. C C-index values of m6A score and clinicopathological parameters for OS in patients with adjuvant chemotherapy in the international cohort. D Kaplan-Meier curves of OS in patients with adjuvant chemotherapy in the NCC cohort. E ROC analysis of m6A score for predicting survival at 1, 3, and 5 years in patients with adjuvant chemotherapy in the NCC cohort. F C-index values of m6A score and clinicopathological parameters for OS in patients with adjuvant chemotherapy in the NCC cohort. G Kaplan-Meier curves of RFS in patients with adjuvant chemotherapy in the NCC cohort. H ROC analysis of m6A score for the prediction of RFS at 1, 3, and 5 years in patients with adjuvant chemotherapy in the NCC cohort. I C-index values of m6A score and clinicopathological parameters for RFS in patients with adjuvant chemotherapy in the NCC cohort

Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us